Protocol Ledger

NCT04160546 · Phase II · COMPLETED

Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)

Interventional Phase II clinical trial protocol NCT04160546 sponsored by Fundacion CRIS de Investigación para Vencer el Cáncer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-01-17 Enrollment: 34 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04160546
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)34 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04160546
Protocol FieldVerified Registry Value
NCT IdentifierNCT04160546
Consolidated Lead SponsorFundacion CRIS de Investigación para Vencer el Cáncer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment34 participants (ACTUAL)
Registered Start Date2020-01-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI